Emergent BioSolutions | EBS - Bienes





Bienes Cambio Fecha
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
ALKERMES USD 4.39B 135.05M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amarin USD 624.36M 21.4M 2026-06
ANI Pharmaceuticals USD 1.49B 72.14M 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Coherus Biosciences USD 191.18M 74.84M 2026-06
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Exelixis USD 2.49B 99.36M 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Heron Therapeutics USD 252.26M 6.05M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Ironwood Pharmaceuticals USD 434.57M 37.66M 2026-03
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
Lonza CHF 18.97B 164M 2025-12
Merck USD 129.8B 1.12B 2026-06
Moderna USD 10.96B 527M 2026-06
Myriad Genetics USD 638.9M 34.8M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Pacira USD 1.24B 35.44M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
United Therapeutics USD 7.22B 505.9M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12